BACKGROUND: While step therapy (ST) policies are generally effective at reducing cost through the managed utilization of targeted medications, the clinical implications of ST policies are not clear and may vary across therapeutic areas. Guanfacine extended-release (GXR) is approved by the FDA for the treatment of attention-deficit/hyperactivity disorder (ADHD) as both monotherapy and adjunctive to stimulant treatment. At the introduction of GXR to the market, Humana implemented an ST policy on GXR requiring the documentation of previous treatment, intolerance, or contraindication to generic clonidine or guanfacine.
OBJECTIVE: To examine the impact of a GXR ST coverage determination (i.e., approved vs. denied) on medication utilization and health care costs among members of a commercial health plan with an ST policy for GXR.
METHODS: This study was a retrospective cohort study of administrative claims data. Humana commercial members prescribed GXR who had an ST coverage determination review were identified. All members included in this analysis were required to be aged 6-17 years, have a diagnosis of ADHD or be receiving stimulant medication, have an ST coverage determination (index event) between September 1, 2009, and May 30, 2012, and have 6 months of pre-and post-index continuous enrollment. Members were assigned to either the approved or denied group based on the outcome of the ST coverage determination. Medical and pharmacy claims data were used to measure baseline demographic and clinical characteristics and to measure medication utilization and health care costs. Outcomes assessed during follow-up included ADHD medication use, proportion of days covered (PDC) with any ADHD medication treatment, time to first observed post-index ADHD treatment, and all-cause and mental health (MH)-related health care costs. Administrative costs associated with the coverage determination process were also estimated. Bivariate and multivariable adjusted analyses were conducted to compare medication utilization and health care costs between the approved and denied groups.
RESULTS: A total of 642 members were included in the analysis (denied group n = 395 [61.5%], approved group n = 247 [38.5%]). The approved and denied groups were similar in terms of baseline demographics, provider characteristics, and baseline MH diagnoses, with the exception of anxiety disorders being more prevalent in the approved group compared with the denied group (18.2% vs. 10.6%, P = 0.006). A denied GXR coverage determination was associated with a greater percentage of members receiving no ADHD treatment post-index (13.9% vs. 
What is already known about this subject
• This study represents a novel analysis of the impact of an ST coverage determination (approval vs. denial) on attention-deficit/hyperactivity disorder (ADHD) medication utilization and health care costs among individuals seeking nonstimulant treatment for ADHD.
• Coverage denial was associated with a lower rate of ADHD treatment, longer time to post-index prescription, and lower proportion of days covered with any ADHD medication during the postreview period.
• After controlling for pre-index costs and other potentially confounding variables, there was no statistically significant difference observed in either all-cause or mental health-related health care costs for members with an approved coverage determination versus members with a denied coverage determination. S tep therapy (ST) is a formulary policy intended to encourage the use of lower-cost medications prior to a member progressing to higher-cost treatment options. 1, 2 In a recent insurance benefit design survey conducted by the Pharmacy Benefit Management Institute, 56% of employer-sponsored drug benefit programs utilized ST for 1 or more medication class. 3 While ST interventions have been shown to be generally effective at reducing utilization and medication expenditures for the target drug, 1,2 examination of the broader implications of ST policies on health care costs and treatment patterns has generated mixed results, particularly among psychotropic medications. [4] [5] [6] [7] In addition, there has been limited examination of the impact of an ST policy in terms of outcomes for individuals who request a formal coverage determination (i.e., an ST override) and are either approved for or denied the restricted medication. In addition, to our knowledge there has been no published research examining the impact of an ST formulary intervention related to attention-deficit/hyperactivity disorder (ADHD) medications.
Recently, there have been new treatment options and new formulations of existing drugs introduced. Several stimulants in immediate-release (IR) tablets have been reformulated into extended-release tablets. Extended-release formulations may reduce fluctuations in medication blood concentration and extend the duration of effect, thereby eliminating the need for additional doses during the day. Intuniv (guanfacine extendedrelease [GXR]) has been approved by the U.S. Food and Drug Administration (FDA) and is a once-daily alpha-2 adrenergic agonist formulation for the treatment of ADHD in children and adolescents aged 6-17 years. GXR has been shown to provide sustained therapeutic concentrations over longer periods, with reduced peak-to-trough fluctuations due to its controlled absorption. 8 From an outcomes standpoint, a retrospective analysis of medical and pharmacy claims data found greater medication adherence; lower rates of inpatient and emergency department admissions; and lower rates of treatment discontinuation, switching, and augmentation among patients treated with GXR compared with guanfacine IR (GIR). 9 While patients treated with GXR in that study had greater pharmacy costs, they had lower medical costs compared with patients treated with GIR, and there was no significant difference in total health care costs (medical and pharmacy costs combined) between the 2 treatment groups. Although not approved by the FDA for the treatment of ADHD, and despite a limited evidence base for IR alpha agonists (clonidine and guanfacine) in the treatment of ADHD, IR alpha agonists have been used off-label as a nonstimulant alternative, combination, or adjunct treatment in patients with ADHD. [10] [11] [12] [13] [14] [15] [16] [17] Given the single retrospective comparative study of GXR versus GIR, and the differential cost between the IR alpha agonists and GXR, the use of an ST formulary intervention may be a potentially appropriate technique for controlling A medication coverage array was used to evaluate ADHD medication use (amphetamine, methylphenidate, atomoxetine, and alpha agonists). The medication coverage array was populated based on the fill date and associated days' supply for each prescription claim. Based on data contained in the array, medication utilization flags were populated for each member with ≥ 30 days of medication coverage. Among members utilizing ADHD medication treatment, combination therapy was defined as ≥ 30 days of overlapping coverage with 2 or more ADHD medication subclasses (with distinction between longand short-acting formulations). Proportion of days covered (PDC) with any ADHD medication was defined as the sum of days covered with any ADHD treatment divided by the number of days in the observation period. Time to post-index ADHD medication claim was defined as number of days between the index date and the first observed prescription claim for any ADHD medication during the post-index period. Cumulative ADHD treatment gap days were defined as the cumulative number of days during which there was no ADHD medication coverage. Non-ADHD MH medication utilization was identified based on the presence of 1 or more prescription claims.
Direct health care costs were measured based on financial data recorded with adjudicated medical and pharmacy claims (allowed paid amount, including plan-and member-paid shares for paid claims), and all costs were adjusted to 2012 dollars based on the Consumer Price Index. Total health care, medical, and pharmacy costs were calculated. For the medical cost component, ICD-9-CM codes associated with medical claims were used to classify expenditures as MH-related costs (ICD-9-CM codes 290.xx-319.xx in any diagnosis position). For the pharmacy cost component, MH-related pharmacy expenditures were determined for MH medication classes (see Appendix B, available in online article). GXR-related ST administrative costs were determined by health plan staff and were based on estimates of time labor, transaction fees, printing, and postage associated with coverage determination processing; however, administrative cost estimates do not include indirect cost of plan operations, such as associate benefits and overhead, or costs associated with development and maintenance of a formulary policy. GXR ST administrative costs were estimated for each member based on the total number of denied and approved GXR-related reviews for that member multiplied by estimated unit cost for denied and approved reviews. Only GXR reviews were considered in the ST administrative cost estimate.
Statistical Analysis
Study measures are summarized with frequency counts and percentages for categorical data; mean and standard deviation (SD) for noncost continuous measures; and median, first quartile, and third quartile for continuous cost measures. Bivariate statistical tests were used to compare the approved and denied groups on baseline demographic and clinical characteristics, medication utilization, and health care costs. Dichotomous and categorical measures were compared between groups using chi-square tests; noncost continuous measures were compared between groups using t-tests; and the Wilcoxon rank-sum test was used to compare health care cost distributions. McNemar's test was used to compare within-group pre-and post-index use of specific non-ADHD MH medication utilization.
A series of a priori prespecified multivariable analyses were conducted to examine the relationship between GXR coverage determination status and study outcomes. GXR coverage determination status was the independent variable of interest in each model. Post-index ADHD medication treatment status (e.g., any ADHD treatment vs. no ADHD treatment) was modeled via logistic regression. The 1 relationship between GXR review status and post-index ADHD medication PDC was modeled via linear regression. Time to first observed post-index ADHD prescription claim was modeled using a Cox proportional hazards model. For the logistic, linear, and Cox proportional hazards models, key demographic and clinical variables were forced into the models, and other baseline variables were allowed to enter each model via automated variable selection (Appendix C, available in online article). To test the sensitivity of the findings to selection algorithm, separate models were fit using backward elimination and bidirectional elimination.
Generalized linear models using a log link and a gamma distribution were used to model post-index health care costs while controlling for the influence of potentially confounding baseline characteristics. Total and MH-related health care costs were modeled. Variables included in the cost models were prespecified and were forced into the model (see Appendix C). All analysis was conducted with SAS version 9.3 (SAS Institute, Carey, NC). Alpha level for all analyses was set at 0.05.
■■ Results Subject Selection and Baseline Characteristics
A total of 642 members who had a diagnosis of ADHD and/or were receiving ADHD medication treatment during the prereview period were identified for the approved (n = 247) or denied (n = 395) groups (see Figure 1 ). There were no statistically significant differences observed in either member demographics or provider characteristics between the 2 groups (Table 1 ). There were no baseline differences observed in the prevalence of MH conditions examined, with the exception of anxiety disorders being more frequently observed in the approved group (18.2% vs. 10.6%, P = 0.006; Table 2 ).
Baseline Medication Utilization
No baseline ADHD medication treatment was observed for 16.6% of members in the approved group and 24.3% of members in the denied group (P = 0.020; Table 2 ). Pre-index alpha agonist and atomoxetine use were observed more frequently in the approved group (6.5% vs. 1.0%, P < 0.001, and 11.3% vs. 6.3%, P = 0.025, respectively). There were no statistically significant between-group differences observed in mean Non-ADHD MH medication utilization during the baseline period was more common among the approved group (41.3% vs. 28.6%, P = 0.001; data not shown in table). Atypical antipsychotic (AAP) utilization was observed more frequently among members in the approved group (22.7% vs. 9.4%, P < 0.001), while frequency of antidepressant (23.4% vs. 18.2%, P = 0.107), anticonvulsant (7.7% vs. 6.3%, P = 0.506), benzodiazepine (2.0% vs. 1.5%, P = 0.631), and the other MH medication categories were similar in both groups (data not shown).
Baseline Health Care Costs
Pre-index all-cause total health care, total pharmacy, MH-related total health care, and MH pharmacy cost distributions differed 
Diagnosis of ADHD or a prescription claim for a stimulant medication during the pre-index observation period was a requirement for inclusion in the on-treatment/indication analysis set. c Medication utilization is a status variable that is determined based on coverage with ≥ 30 days of medication supply during the given observation period. No ADHD medication category is equal to the number of members with no ADHD medication utilization (i.e., < 30 coverage days within any class) during pre-index period. Medication utilization categories are not mutually exclusive. d Combination treatment defined as ≥ 30 days coverage with 2 or more medication subclasses (including long-and short-acting formulations). ADHD = attention-deficit/hyperactivity disorder; OCD = obsessive compulsive disorder; ODD = oppositional defiant disorder; PDC = proportion of days covered; PDD = pervasive developmental disorder; SD = standard deviation.
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non-ADHD MH medication categories examined. An increase in any non-ADHD MH medication use pre-to post-index was observed within the denied group (28.6% vs. 32.2%, P = 0.048; data not shown); however, non-ADHD MH medication use did not differ pre-to post-index in the approved group (41.3% vs. 42.5%, P = 0.622; data not shown). Unadjusted post-index health care costs are summarized in Table 5 . Median all-cause and MH-related total health care costs were greater for the approved group in the unadjusted analyses (both P < 0.001). There were no statistically significant differences between groups in medical costs; however, median all-cause and MH-related pharmacy costs were greater in the approved group (both P < 0.001). ST administrative costs were greater in the denied group (P < 0.001).
Multivariable Adjusted Analyses
For the linear regression and Cox proportional hazards models, backward elimination and bidirectional elimination resulted in identical models. For the logistic regression model, the 2 variable selection algorithms resulted in inclusion of different variables; however, the results from both models were similar in terms of magnitude and significance (Appendices D-I, available in online article).
After controlling for potentially confounding variables, the odds of observing treatment with any ADHD medication during the post-index period were lower among members with a denied GXR coverage determination compared with those with an approved coverage determination (odds ratio = 0.18, 95% confidence interval [CI] = 0.08-0.42). In the multivariable adjusted model of PDC, GXR coverage approval was associated with a 14 percentage point increase (95% CI = 10-18 percentage points) in the PDC with any ADHD medication during the post-index period (regression coefficient [B] = 0.14, standard error [SE] = 0.02, P < 0.001). GXR coverage denial was associated with a lower hazard rate (HR) for observation of a significantly between the approved and denied groups (Table 3) . In each of these cases, median cost estimates were greater among the approved than the denied group (P < 0.050 for all). There were no statistically significant differences in baseline all-cause (P = 0.199) or MH-related medical costs (P = 0.135). Table 4 ). No post-index ADHD medication treatment was observed more frequently in the denied than the approved group (13.9% vs. 3.2%, P < 0.001). There were no statistically significant differences observed in terms of the frequency of post-index amphetamine, methylphenidate, or atomoxetine use between groups; however, alpha agonist use was lower among the denied group (49.6% vs. 89.9%, P < 0.001). GXR utilization was less common among members with a denied GXR coverage determination (14.7% vs. 88.3%, P < 0.001), while GIR and CIR utilization was more frequent among the denied group (42.8% vs. 5.3%, P < 0.001, and 6.3% vs. 2.0%, P = 0.012, respectively). A higher proportion of members in the approved group were observed to be on adjunctive treatment during the post-index period (44.9% [n = 111] vs. 28.9% [n = 114], P < 0.001). In the approved group, most members on adjunctive treatment were receiving a combination of stimulant plus GXR (86.5%, n = 96), while those in the denied group received a stimulant plus GIR (48.2%, n = 55; data not shown).
Post-Index Measures
Similar to baseline, post-index AAP use was more frequent in the approved group (20.6% vs. 10.4%, P < 0.001; data not shown). Post-index antidepressant utilization was also greater in the approved group (28.3% vs. 21.5%, P = 0.049; data not shown). There were no other differences observed in the receive any ADHD treatment during the postreview period. These findings are generally aligned with previous research in other therapeutic areas, indicating that a substantial portion of patients do not receive prescription medication treatment following ST edit at the point of sale. 19, 20 In the context of children and adolescents with ADHD, lack of treatment can have significant consequences, manifesting in school-related difficulties and psychosocial impairment. 21 Furthermore, only 50% of members who were denied coverage for GXR received any alpha agonist treatment (primarily GIR) during the post-index period, suggesting limited effectiveness in directing members who were requesting GXR to the less expensive CIR or GIR. There was no difference in postindex amphetamine, methylphenidate, or atomoxetine utilization observed between the approved and denied groups, suggesting that there was not an obvious compensatory increase in stimulant treatment among members with a denied coverage determination.
Another potential unintended consequence observed was that members in the approved and denied groups displayed degrees of treatment discontinuity. The PDC with any ADHD medication was significantly lower among members in the denied group. Similarly, substantial treatment gap days were observed in both groups, with a greater number of treatment gap days among the denied group. There was also an observed post-index prescription claim for any ADHD medication (B = −0.65, SE = 0.09, HR = 0.52, P < 0.001). There was no statistically significant relationship observed between GXR coverage denial and either all-cause total costs (B = −0.07, SE = 0.08, P = 0.393) or MH-related total costs (B = −0.15, SE = 0.08, P = 0.054) in the multivariable adjusted cost analysis.
■■ Discussion
To our knowledge, this study represents the first analysis of outcomes associated with an ST formulary policy in ADHD, and the first to examine medication utilization and health care costs based on outcome of a coverage determination review.
2,18
Results indicate that a coverage review denial was associated with a lower rate of treatment for ADHD, greater delay in receiving ADHD treatment, and lower PDC with any ADHD treatment. These findings were evident in unadjusted comparisons and analyses that controlled for baseline differences in demographic and clinical characteristics among the study groups.
As expected, GXR utilization during the post-index period was less common among denied than approved members. However, there may have been unintended consequences related to the ADHD treatment, including reduced ADHD medication utilization overall. Approximately 14% of members in the denied group and 3% in the approved group did not 
Combination treatment defined as ≥ 30 days coverage with 2 or more medication subclasses (including long-and short-acting formulations). ADHD = attention-deficit/hyperactivity disorder; PDC = proportion of days covered; SD = standard deviation.
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delay in terms of the time from initiation of the coverage determination review process to receipt of any ADHD treatment during the post-index period. The average time to postreview ADHD prescription was more than 2-fold longer in the denied than the approved group. A substantial body of evidence demonstrates that untreated ADHD has a negative impact on longterm outcomes, such as academic performance and psychosocial functioning, and that treatment for ADHD is associated with positive impact on social, academic, and behavioral health outcomes. [22] [23] [24] [25] While medication adherence is closely associated with short-term treatment response, 26 the clinical impact of short-term, involuntary delay or discontinuity in treatment is not clear and warrants further research.
ST policies are generally associated with prescription drug savings at the plan level but may be associated with increased medical service utilization and total health care expenditures. In this study, pre-and post-index unadjusted total health care and total pharmacy costs were lower among members in the denied group. The unadjusted health care costs for the approved group may have been higher as a result of greater level of MH-related comorbidity (e.g., anxiety disorders), greater pre-index medication utilization, or other factors. After controlling for potentially confounding baseline characteristics including pre-index health care costs and MH-related comorbidity between groups, no differences were observed in all-cause total health care or MH-related total health care costs.
ST formulary policies directly impact medication utilization by halting adjudication of the prescription claim at the point of service. In response to an ST edit, the provider must be contacted by either the patient or the pharmacist in order to amend the prescription order of the first-line agent or for the provider to request a coverage determination from the health plan. In a survey of health plan members subject to ST for proton pump inhibitors and nonsteroidal anti-inflammatory medications, approximately 20% of members reported that neither they nor their pharmacists contacted the prescribing physicians after a point-of-service ST rejection. 27 The current study focused on treatment patterns and economic outcomes in an insured population for patients who engage with the ST coverage determination process and requested a coverage determination typically through their physicians. This analysis may underestimate the total effect of a ST policy on overall medication utilization patterns and economic outcomes in other populations. For example, ST policies may also impact medication utilization indirectly. Previous research has demonstrated that a formulary policy implemented in 1 market segment (e.g., Medicaid) is associated with a "spillover" effect on prescribing behaviors in other market segments (e.g., commercial health plans). 28 Further research is necessary to address the broader implications of an ST policy in the ADHD therapeutic area and other populations of ADHD (e.g., adults).
Limitations
Several limitations apply to this study. Although the study groups did not appear to be different in observed measures, they may differ on clinical measures, such as symptomatic or functional impairments that are not specified within claims data. In addition, certain factors that may impact the study outcomes may not be possible or practical to operationalize via claims data. For example, time since initial diagnosis of ADHD and time since initial treatment for ADHD were identified as potentially relevant variables during the design of the study; however, determination of condition onset and time since initial medication treatment was determined to be impractical within the context of the available claims data. Although these specific variables were not included in our study, we attempted to incorporate a broad range of plan, provider, clinical, demographic, and socioeconomic characteristics that could influence study outcomes.
Analysis of medication utilization based on pharmacy claims data is predicated on health plan members using their pharmacy benefits and comprehensive capture of medication utilization via prescription claims. Previous research suggests that, in response to an ST edit, members may obtain prescription medication outside of the pharmacy benefit (e.g., by paying out-of-pocket for medication). 27, 29 In addition, shunting of health plan members to these alternative channels may be associated with lower member satisfaction with pharmacy benefits. 29 As is the case with previous claims-based studies examining the impact of an ST policy on medication utilization, 19, 20 medication utilization facilitated through channels outside the pharmacy benefit are not assessed in the current study.
We assessed health care costs based on financial data associated with paid medical and pharmacy claims. Medication costs for drugs obtained outside the pharmacy benefit (e.g., by paying out-of-pocket for medication) are not captured in claims data. Costs associated with administration of the coverage determination process are important considerations from the health plan perspective and have not typically been included in previous research. 1 Our analysis included unit cost estimates for approved and denied claims based on time labor, transaction fees, printing, and postage associated with coverage determination processing. Other administrative costs related to development and maintenance of a medication formulary, utilization management policies, and other health plan operations were not included in our administrative cost estimates. Thus, the administrative cost included in this study is an underestimate of the total cost associated with developing, maintaining, and administering a specific formulary policy.
A cause-effect relationship cannot be established based on this study, since it is an observational study based on retrospective claims data. Although multiple regression modeling was used in this analysis to control for potential confounding related to between-group differences in baseline demographic and clinical factors, this approach can only reduce bias caused by appropriately measured covariates that are included in the statistical models. Variables that are not measured or recorded in the administrative claims data may represent a study bias. These results are valid to the health plan and membership examined but may not be generalizable to other populations or plans (e.g., Medicaid).
■■ Conclusions GXR coverage determination denial, compared with approval, was associated with a lower rate of ADHD medication utilization as measured by pharmacy claims, greater delay in receiving ADHD treatment, and lower PDC with ADHD treatment. No differences were observed between the approved and denied groups in terms of all-cause total health care or MH-related total health care costs after controlling for relevant variables including pre-index costs. Payers should consider the potentially unintended consequences of ST policies, in particular treatment discontinuity and under treatment, when developing and implementing policies in the ADHD therapeutic area. 
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